Real‐world prevalence and consequences of potential drug‐drug interactions in the first‐wave COVID‐19 treatments-Reference-Cited by-同舟云学术

Real‐world prevalence and consequences of potential drug‐drug interactions in the first‐wave COVID‐19 treatments

Published:2020-12-23 Issue:3 Volume:46 Page:724-730
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Martínez‐López‐de‐Castro Noemí¹^ORCID,Samartín‐Ucha Marisol¹,Paradela‐Carreiro Adolfo²,Pérez‐Landeiro Antonio²,Inaraja‐Bobo María Teresa²,Álvarez‐Payero Miriam¹,Castro‐Núñez Inés²,García‐Beloso Nerea²,Robles‐Torres David²,López‐López Aida²,González‐Costas Sonia²,Leboreiro‐Enríquez Belén²,Otero‐Millán Luis²,Yaiza Romero‐Ventosa Elena³,Casanova‐Martínez Cristina²,Lorenzo‐Lorenzo Karina²,Regueira‐Arcay Ana María²,Vázquez‐López Cristina²,Martínez‐Reglero Cristina⁴,Piñeiro‐Corrales Guadalupe²

Affiliation:

1. Department of Pharmacy University Hospital Complex of Vigo IRIDIS (Investigation in Rheumatology and Immune‐Mediated Diseases) Group Galicia Sur Health Research Institute SERGAS‐UVIGO Vigo Spain

2. Department of Pharmacy University Hospital Complex of Vigo Vigo Spain

3. Department of Pharmacy University Hospital Complex of Vigo. NeumoVigo I+i Research Group. Sur Health Research Institute. SERGAS‐UVIGO Vigo Spain

4. Methodology and Statistics Unit Galicia Sur Health Research Institute (IIS Galicia Sur SERGAS‐UVIGO Vigo Spain

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13337

Reference18 articles.

1. First cases investigated in Spain of Covid‐2019.Report No. 1. Ministry of Health and Social Services. Access June 2020. Available at:https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-19.%20N%c2%ba%201_11febrero2020_ISCIII.pdf

2. Update No 138. Coronavirus (COVID‐19) disease. 27.10.2020.Center of coordination of Alerts and Sanitary Emergencies. Ministry of Health and Social Services. Access October 2020. Available athttps://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_237_COVID-19.pdf

3. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

4. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019

5. Available treatments under special access conditions for the management of respiratory infection by SARS‐CoV‐2. Spanish Medicines Agency and Sanitary Products. Access June 2020. Available athttps://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%e2%80%9119/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2/

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A cross-sectional study on the potential drug-drug interaction risk of COVID-19 patients in hospital;Int. Journal of Clinical Pharmacology and Therapeutics;2024-07-01

2. Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities;PeerJ;2023-06-28

3. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy;Journal of Managed Care & Specialty Pharmacy;2023-05

4. Identification of Drug Interaction Adverse Events in Patients With COVID-19;JAMA Network Open;2022-04-19

5. Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments;International Journal of Environmental Research and Public Health;2021-11-08